Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-842-0 | CAS number: 75-12-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Formamide was of mild toxicity in repeated dose studies using rats and mice. The oral NOAEL was 40 mg/kg bw/day for female rats (males: 80 mg/kg/day) and male and female mice in 90-day studies, based on hematological changes. In a dermal 90-day rat study, the NOAEL was 100 mg/kg bw, based on hematological changes in both sexes. The inhalation NOAEL was 0.19 mg/L, based on mild hematological changes in both sexes of the rat.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 40 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Reliable without restrictions. The study was conducted similar to OECD guidelines and under GLP conditions.
- System:
- haematopoietic
- Organ:
- blood
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEC
- 190 mg/m³
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Reliable without restrictions. The study was conducted similar to OECD guidelines and under GLP conditions.
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Reliable without restrictions. The study was conducted according to OECD guidelines and under GLP conditions.
Additional information
Oral:
Doses of formamide up to 160 mg/kg bw/day for 3 months produced a relatively mild toxic response in rats received 10, 20, 40, 80, and 160 mg/kg bw/day in a subchronic oral gavage study similar to OECD TG 408 (Key study). Most effects were observed in groups that received the highest dose of 160 mg/kg bw/day and consisted of 20% to 25% body weight reductions and an increase in the erythron that was evidenced by increases in hematocrit values, hemoglobin concentrations, and erythrocyte counts. The only microscopic lesion identified was degeneration of the germinal epithelium in the testes and epididymis of 160 mg/kg bw/day male rats. Slight body weight reductions also occurred in groups that received 80 mg/kg bw/day and in females that received 40 mg/kg bw/day; however, few other changes were noted at these doses.
The mechanism of blood cell changes is still unclear. Bone marrow hyperplasia was seen in the 2 -year studies.
Formamide was not hepatotoxic in rats, other than N, N-dimethyl formamide and N-methyl formamide. It was therefore suggested that the formamide metabolism is different from that of the methylated formamides.
The estimated split NOAEL values are 80 mg/kg bw/day for males, based on the reduced body weight (-25%), erythron changes, and histopathological changes (degeneration of the germinal epithelium) in the testes and in the epididymis, and 40 mg/kg bw/day for females, based on reduced body weights (-20%) at 160 mg/kg bw/day and hematological changes at 80 mg/kg bw/day (Key study).
Dermal:
In a subchronic dermal study that was conducted according to OECD guideline 411 and under GLP conditions, formamide was applied to the intact skin of Wistar rats ((0, 30, 100, 3000 mg/kg body weight/day; 10 male and 10 female rats per dose; 20 animals in the high dose groups). Formamide was applied at a constant volume, i.e. it was undiluted at the high dose and diluted with water at the two other dose levels. The control animals received only water.
In groups at 3000 mg/kg bw/day substance related mortality (3/20, only males), clinical signs of toxicity in both sexes (prostration, apathy), reduced food consumption, reduced body weight were seen. Statistically significant changes compared to the controls were noted as follows: Hematological changes included increases in erythrocyte count, hematocrit, hemoglobin and mean corpuscular hemoglobin content, and reticulocyte counts. Leucocytes were reduced in both sexes and platelets only in males.
Pathological findings included reduced body weights in both sexes; decrease in absolute organ weights of liver, kidney, spleen, testes and adrenals of males; increase in relative liver and kidney weights (both sexes) and of the adrenals in males; increased number of rats with bilateral testicular tubular atrophy.
No treatment-related effects were noted in groups at 100 and at 30 mg/kg bw/day.
The
NOAEL for subchronic dermal administration was therefore established
at 100 mg/kg bw/day (Key study).
Inhalation:
In an inhalation study that was conducted similar to OECD TG 412, three groups of 10 male CrLCD BR rats each were exposed nose-only for 6 hr/day, 5 days/week for 2 weeks to design concentrations of 100, 500, or 1500 ppm of formamide aerosol in air (Key study). A control group of 10 male rats was exposed simultaneously to air only. 50% of the animals were sacrificed on study day 12 after 10 exposures, the remaining animals were allowed a 14 day recovery. Statistically significantly reduced body weights, histopathological changes in the kidneys, and reduced platelet counts were seen in rats at 1500 ppm. Rats at 500 ppm showed reduced platelet counts only.
The NOAEC for repeated inhalation of formamide in rats was considered to be 100 ppm or 0.19 mg/kg bw/day, based on the hematologic and clinico-chemical parameters measured at 500 ppm (in particular thrombocytopenia). The biological relevance of this effect was considered equivocal. 100 ppm corresponds to 0.187 mg/L [which is far above the vapour saturation concentration of 0.055 mg/L], or 54 mg/kg bw/d, calculated on the basis of default physiological parameters [R8, page 26: rat body weight: 0.25 kg; rat respiratory volume, 6h: 0.29 m³).
Justification for classification or non-classification
Oral route of exposure:
Based on the findings on the blood system as observed in the available repeated dose toxicity studies with an oral administration route, the registered substance is classified as STOT RE Category 2 (H373) according to Regulation (EC) No 1227/2008 (CLP).
Inhalative and dermal route of exposure:
Based on the results of the repeated dose toxicity studies with inhalative and dermal administration routes, the registered substance is not classified according to Regulation (EC) No 1227/2008 (CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.